Pharvaris raises $66M series B for clinical development of oral HAE therapy

Pharvaris will use its new $66 million series B round to fund early clinical development of its lead compound, an oral small molecule that could give HAE patients an easier-to-use option than existing injectable therapies by treating the disease both prophylactically and on-demand.

Pharvaris B.V. (Leiden, Netherlands) said Tuesday it had started a Phase I trial in healthy volunteers of PHA121, a bradykinin B2 receptor (BDKRB2; BR2) antagonist that targets a GPCR receptor downstream of the missing complement protein in hereditary angioedema...